HCPCS Q5136: Denosumab-bbdz (Jubbonti/Wyost) Injection, 1 mg
HCPCS Level II code Q5136 denotes the injection of denosumab-bbdz (Jubbonti/Wyost), a biosimilar formulation of denosumab, at a 1 mg unit. This code matters nationally as biosimilar biologics expand therapeutic options and impact drug pricing, utilization patterns, and payer coverage policies across outpatient and infusion settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for denosumab biosimilars, the typical service settings in which Q5136 is billed, and the payer landscape relevant to coverage and reimbursement. The publication outlines national benchmarks where available, summarizes recent policy updates affecting biosimilar injectable coverage decisions, and explains implications for billing and claims workflows.
This summary equips clinicians, billing professionals, and policy analysts with a clear understanding of what Q5136 represents, which payers commonly encounter the code, and the topics covered in the full publication: utilization benchmarks, coverage policy trends for biosimilars, and clinical context for denosumab use. Data not available in the input will be explicitly noted in the detailed sections.
Sign up for hcpcs Q5136 policy alerts
Get alerted when payer policies referencing Q5136 are released or updated.
Billing Code Overview
HCPCS Level II code Q5136 represents an injection of denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg. This billing entry denotes the administration of a biosimilar version of denosumab, an antiresorptive monoclonal antibody used in conditions requiring inhibition of bone resorption.
Service Type: Drug administration / injectable biologic
Typical Site of Service: Outpatient infusion clinic, physician office, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or adult patient with osteoporosis or bone loss who requires subcutaneous monoclonal antibody therapy to reduce fracture risk. The patient presents to an outpatient infusion clinic, specialty injectable clinic, or physician office for administration of denosumab-bbdz (Q5136) dosed per product labeling. Clinical workflow includes verification of indication and recent bone mineral density or fracture history, medication reconciliation, screening for hypocalcemia and recent dental procedures, obtaining informed consent, documentation of lot number and dose, subcutaneous injection by an authorized clinician (e.g., nurse, advanced practice provider, or physician), observation for immediate adverse reaction (typically 15–30 minutes), and scheduling of follow-up dosing and monitoring (calcium, vitamin D adherence, and dental evaluation as indicated). Typical sites of service are outpatient infusion/injectable clinics, physician offices, and ambulatory care centers; administration may also occur in long-term care facilities for eligible residents.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use for routine, single-product administration when no special circumstances apply |
22 | Increased procedural services | Use when substantially greater work is performed related to counseling, coordination, or documentation for the injection beyond typical administration |
23 | Unusual anesthesia | Rarely used; only if unusual anesthesia unrelated to the injection is required |
52 | Reduced services | Use if only a portion of the planned service is performed (e.g., partial dose due to adverse event) |
53 | Discontinued procedure | Use when administration is started but discontinued for patient safety reasons |
62 | Two surgeons | Use when two physicians with different specialties share responsibility for a related invasive procedure (rare for this injection) |
78 | Return to operating/procedure room for a related procedure by same physician | Use if patient requires return to procedure area for management of a complication related to the injection |
80 | Assistant at surgery | Use when an assistant participates in a related surgical procedure (uncommon for subcutaneous injection) |
AS | Physician assistant, nurse practitioner, clinical nurse specialist services for assistant at surgery | Use when an advanced practice clinician performs or assists with the injection under appropriate supervision rules |
CQ | Service delivered under physician supervision by a clinical staff member | Use when the product is administered by clinical staff under direct physician supervision and payer requires the modifier |
JW | Drug amount discarded/not administered to patient | Use when a portion of a single-use vial or syringe is discarded and must be reported per payer policy |
JZ | No drug amount discarded | Use to indicate full vial/syringe was administered with no discard when payers require explicit reporting |
PN | Items or services furnished pursuant to a non-physician practitioner (NPP) plan of care | Use when administered under an NPP’s plan of care as allowed by state law and payer rules |
QX | Ordered/referred by a physician by certain contractual arrangements | Use when required by payer rules to indicate physician ordering and oversight |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Family Medicine | Common site for prescription and administration of osteoporosis biologic therapy |
207Q00000X | Internal Medicine | Frequently manages chronic bone disease and prescribes denosumab-bbdz |
261QM0800X | Nurse Practitioner | Administers and documents injections in outpatient settings under supervision or collaborative practice |
363A00000X | Clinical Nurse Specialist | Provides specialized nursing management and administration in infusion clinics |
208600000X | Geriatric Medicine | Manages older adults with osteoporosis and coordinates long-term care administration |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M80.00XA | Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture | Denosumab-bbdz is indicated for osteoporosis to reduce fracture risk; this code reflects osteoporosis with fracture |
M81.0 | Age-related osteoporosis without current pathological fracture | Common indication for initiation of denosumab-bbdz for fracture prevention in postmenopausal adults |
M80.08XA | Age-related osteoporosis with current pathological fracture, all sites, initial encounter for fracture | Used when osteoporosis is accompanied by fracture at multiple or unspecified sites |
M81.8 | Other osteoporosis without current pathological fracture | Alternative osteoporosis diagnosis where biologic therapy may be considered when risk factors present |
Z79.51 | Long term (current) use of antithrombotics/antiplatelets | Relevant as co-therapy or coexisting medication that may affect procedure planning or bleeding risk assessment |
E83.51 | Hypocalcemia | Important to screen and correct before administration of denosumab-bbdz because of risk of post-dose hypocalcemia |
Z79.899 | Other long term (current) drug therapy | Captures chronic medication use that may be documented in the context of biologic therapy management |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Commonly reported for the professional administration service when a single subcutaneous injection of denosumab-bbdz is given in an office or clinic |
36415 | Collection of venous blood by venipuncture | Often performed before or after administration to obtain labs such as serum calcium or renal function for monitoring |
96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | May be billed if IV access and hydration or IV medications are provided as part of managing a reaction (rare for subcutaneous denosumab-bbdz) |
99406 | Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes | Counseling codes such as this or other E/M or counseling codes may be reported if significant counseling about fracture risk reduction is performed at the visit |
99441 | Telephone evaluation and management service by a physician or other qualified health care professional, 5-10 minutes of medical discussion | Post-administration phone follow-up for adverse event assessment or medication adherence counseling may be reported when payer policy permits |